Untitled case

This case, IPR2025-01574, is an Inter Partes Review (IPR) before the Patent Trial and Appeal Board (PTAB), initiated by Unified Patents PTAB Data. Unified Patents is a member-based organization that operates as a defensive aggregator, strategically challenging patents held by Non-Practicing Entities (NPEs), often referred to as "patent trolls," to deter unsubstantiated patent assertions and reduce litigation for its members. They do not pay money to NPEs but rather aim to improve patent quality through actions like filing post-grant challenges. The identity of the current patent owner for U.S. Patent No. 11,126,889 is not readily available through general public search databases; however, given Unified Patents' business model, it is highly probable that the patent owner is a Non-Practicing Entity (NPE) or a similar patent assertion entity.

The sole patent at issue is U.S. Patent No. 11,126,889, titled "Polymeric drug delivery systems for treatment of disease." This patent generally relates to compositions and nanoparticle formulations designed to deliver therapeutic compounds, such as chemotherapeutic agents, to a subject for the treatment of diseases like cancer, specifically mentioning pancreatic ductal adenocarcinoma. Since this is an IPR proceeding, there isn't a directly "accused product" in the context of infringement litigation. Instead, Unified Patents is challenging the patentability of the claims within Patent No. 11,126,889. While no specific related district court litigation involving this patent was identified through public search, IPRs are typically filed in response to, or in anticipation of, infringement assertions in district court.

The procedural posture of the case is an IPR before the Patent Trial and Appeal Board (PTAB), and institution has been granted. This signifies that the PTAB has determined there is a reasonable likelihood that at least one challenged claim of the patent is unpatentable, thus proceeding to a full trial on the merits. The PTAB provides a specialized forum for challenging patent validity, often offering a more efficient and cost-effective alternative to district court litigation. The case is notable as it falls within Unified Patents' broader strategy of proactively addressing alleged "bad patents" asserted by NPEs. The current climate at the PTAB, characterized by increased discretionary denials in IPR petitions, makes the institution of this IPR particularly noteworthy, suggesting that the petition presented a compelling challenge to the patent's validity.

IPR2025-01574: Key Legal Developments

The case IPR2025-01574 concerns an Inter Partes Review (IPR) proceeding before the Patent Trial and Appeal Board (PTAB) challenging U.S. Patent No. 11,126,889. The petitioner in this IPR is associated with Unified Patents PTAB Data. [cite: 4 (previous search result)]

As of the current date, May 28, 2026, the information available indicates a discrepancy regarding the status of IPR2025-01574. While the provided case metadata states the IPR is "Pending - Instituted," direct public search results for this specific IPR and patent do not definitively confirm an institution decision. The general trend for IPRs filed in 2025 shows a significant increase in discretionary denials by the PTAB and the USPTO Director, particularly due to considerations related to parallel district court litigation (known as Fintiv factors) and the "settled expectations" of the parties. [cite: 2 (previous search result), 4, 5 (previous search result), 9 (previous search result), 10 (previous search result)] Since October 2025, USPTO Director John Squires has personally assumed authority over all IPR and Post-Grant Review (PGR) institution decisions, often issuing summary notices without detailed explanations. [cite: 2 (previous search result), 5 (previous search result), 10 (previous search result)]

Missing Information:

Crucially, specific details regarding the Patent Owner of U.S. Patent No. 11,126,889 in the context of this IPR, the exact filing date of the petition for IPR2025-01574, and the specific decision on institution (Paper number, date, and reasoning) are not publicly available through the conducted searches. Furthermore, no parallel district court patent infringement litigation asserting U.S. Patent No. 11,126,889 could be identified. Without such a district court case, a detailed chronological summary of "patent infringement litigation" developments, including pleadings, motions, claim construction, discovery, trial, and final disposition, cannot be provided.

Summary of Known PTAB IPR Developments (based on general 2025 trends and the given "Instituted" status):

• Petition Filing: Unified Patents (or an entity associated with Unified Patents PTAB Data) likely filed the petition for IPR2025-01574 sometime in mid-to-late 2025. For example, a closely numbered IPR, IPR2025-01565, had a filing date of September 25, 2025.
• Preliminary Response & Discretionary Denial Briefing: Following the petition, the Patent Owner would have had the opportunity to file a preliminary response to oppose institution, potentially including arguments for discretionary denial, within three months of the petition's filing date. In 2025, a new bifurcated process was formalized in March 2025, where the Director first decided discretionary considerations before a PTAB panel addressed the merits. [cite: 5 (previous search result)] Patent owners were given a dedicated brief to press discretionary denial arguments. [cite: 5 (previous search result)]
• Institution Decision: Given the prompt's status "Instituted," the PTAB (or the USPTO Director, considering the 2025 changes) decided to institute the IPR. This decision would have been made within approximately six months of the petition filing date. However, no specific documentation confirming the institution of IPR2025-01574 was found in public search results. Many IPRs in 2025 faced discretionary denial, often based on Fintiv factors, such as the proximity of a parallel district court trial date, the overlap of parties and issues, and the investment already made in district court proceedings. [cite: 1 (previous search result)] "Settled expectations" regarding the patent's validity were also a significant factor in discretionary denial decisions.
• Trial Phase (if instituted): If instituted, the IPR would proceed to a trial phase, generally lasting up to twelve months, culminating in a Final Written Decision. [cite: 3 (previous search result)]

Without specific docket information for IPR2025-01574 and any related district court litigation involving Patent 11,126,889, a more detailed chronological account of legal developments is not possible.

Unified Patents PTAB Data, the plaintiff in this IPR, often utilizes external law firms to handle its PTAB proceedings, though it also employs in-house patent counsel. While specific counsel for IPR2025-01574 are not explicitly named in the search results, Unified Patents frequently works with prominent intellectual property law firms for its IPR petitions.

Based on general information regarding Unified Patents' activities and common practices in PTAB litigation, here are some insights into their legal representation:

Likely External Counsel (Firm, based on frequent appearances for petitioners in PTAB):

• Fish & Richardson PC
  • Role: Likely lead counsel.
  • Office Location: Various offices across the US.
  • Experience: Fish & Richardson is consistently ranked among the top firms for petitioners' counsel in PTAB proceedings, demonstrating extensive experience in IPRs.
• Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • Role: Likely lead counsel.
  • Office Location: Various offices across the US and internationally.
  • Experience: Finnegan is another highly active firm in PTAB, frequently representing petitioners in IPRs.
• Haynes & Boone LLP
  • Role: Likely lead counsel.
  • Office Location: Various offices across the US.
  • Experience: Haynes & Boone also appears frequently as petitioners' counsel in PTAB cases.

Unified Patents In-House Counsel:

Unified Patents employs in-house legal staff, including Senior Patent Counsel, who manage patent office proceedings internally, draft petitions, and support external counsel.

• Jonathan Stroud
  • Role: Chief IP Counsel.
  • Firm: Unified Patents.
  • Experience: Involved in discussions regarding reform proposals for improving patent quality.
• Jordan Rossen
  • Role: Senior Patent Counsel.
  • Firm: Unified Patents.
  • Experience: Participates in webinars on PTAB interactions.
• Jessica Marks
  • Role: Senior Patent Counsel.
  • Firm: Unified Patents.
  • Experience: Speaker on amplifying underrepresented voices at the PTAB.
• Michelle Aspen
  • Role: Senior Patent Counsel.
  • Firm: Unified Patents.
  • Experience: Panelist discussing Fintiv denials in light of ITC cases.
• Ellyar Barazesh
  • Role: Senior Patent Counsel.
  • Firm: Unified Patents.
  • Experience: Speaker on strategies for filing Ex Parte Reexaminations.
• Ashraf Fawzy
  • Role: Legal Head - SEP.
  • Firm: Unified Patents.
  • Experience: Speaker on the USPTO's Request for Comments on Discretionary Denials.

It is important to note that without direct access to the docket for IPR2025-01574, identifying the exact counsel of record is not possible. The firms and individuals listed above are based on Unified Patents' known legal activities and common counsel choices for PTAB cases.

Despite extensive web searches using various queries related to IPR2025-01574, U.S. Patent No. 11,126,889, and Unified Patents PTAB Data, the identity of the patent owner (defendant in this IPR context) and their counsel of record could not be definitively identified from the provided search results.

The search results primarily contained general information about Inter Partes Reviews (IPRs), Unified Patents' role as a petitioner, and discussions of other IPR cases. No specific docket entry or official USPTO assignment record for patent 11,126,889 was found that would name the current owner or their legal representation for IPR2025-01574. The USPTO Assignment Center is the authoritative source for patent ownership information, but direct access and search execution through the provided snippets were not possible. Therefore, specific counsel information cannot be provided at this time.